Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Sinopharm, Fosun, Meheco Join to Form $157 Million PE Fund

publication date: Jun 26, 2012
A group of China’s biggest pharma companies have banded together to form a Private Equity Fund that will total 1 billion RMB ($157 million). Sinopharm Capital, a subsidiary of the drug distributing giant Sinopharm, is the General Partner. Limited Partners include Sinopharm’s parent CNPGC, Fosun Pharma and China Meheco. The fund can invest in several sectors of the healthcare industry, including medical treatment, service, manufacturing, distribution, and R&D. More details....

Stock Symbols: (HK: 1099) (SHA: 600196) (SHA: 600056)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China